EUROPEAN COMMISSION

Brussels, 21.12.2009
C(2009)10697

COMMISSION DECISION

of 21.12.2009

amending the marketing authorisation for "Thelin - Sitaxentan sodium", a medicinal product for human use, granted by Decision C(2006)3721

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

COMMISSION DECISION

of 21.12.2009

amending the marketing authorisation for "Thelin - Sitaxentan sodium", a medicinal product for human use, granted by Decision C(2006)3721

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[1],

Having regard to Commission Regulation (EC) No 1085/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation falling within the scope of Council Regulation (EEC) No 2309/93[2], and in particular the third subparagraph of Article 4(5), and the first subparagraph of Article 6(10) thereof,

Having regard to the application submitted by Encysive (UK) Limited on 21 December 2008 under Article 6(1) of Commission Regulation (EC) No 1085/2003,

Having regard to the notification submitted by Encysive (UK) Limited under Article 4(1) of Regulation (EC) No 1085/2003,

Having regard to the opinion(s) of the European Medicines Agency, formulated by the Committee for Medicinal Products for Human Use on 19 November 2009,

Whereas:

(1) An examination of the major variation(s) type II to the terms of the marketing authorisation for the medicinal product "Thelin - Sitaxentan sodium", which is entered in the Community Register of Medicinal Products under number(s) EU/1/06/353/001-005 and the placing on the market of which was authorised by Decision C(2006)3721 of 10 August 2006, has shown that the product remains in compliance with the requirements set out in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use[3].

(2) It is therefore appropriate to accept the application(s) in respect of (a) major variation(s) to the terms of the marketing authorisation and to amend Decision C(2006)3721 accordingly.

---

1 OJ L 136, 30.4.2004, p. 1.
2 OJ L 159, 27.6.2003, p. 24.
3 OJ L 311, 28.11.2001, p. 67.

(3) The European Medicines Agency acknowledged, between 28 September 2009 and 19 November 2009, the validity of the notification(s) for minor variations of type IA, informing the marketing authorisation holder accordingly, and has prepared a list of the notification(s). The variation(s) took effect from the date of the communication from the European Medicines Agency concerning the validation.

(4) The marketing authorisation should be updated, and Decision C(2006)3721 amended accordingly.

(5) For the sake of clarity and transparency, it is advisable, following the amendment of part or parts of the Annexes, to provide for a consolidated version thereof. The Annexes to Decision C(2006)3721 should therefore be replaced,

HAS ADOPTED THIS DECISION:

Article 1

Decision C(2006)3721 is amended as follows:

1) The following list of notifications for minor variations is added to the updated marketing authorisation.

Application number	Scope (EU numbers affected)
EMEA/H/C/679/IA/25	9 (IA) (EU/1/06/353/001-005)

2) Annex I is replaced by the text set out in Annex I to this Decision;

3) Annex II is replaced by the text set out in Annex II to this Decision;

4) Annex III B is replaced by the text set out in Annex III B to this Decision.

Article 2

This Decision is addressed to Encysive (UK) Limited, Alder Castle House, 10 Noble Street, London EC2V 7QJ, United Kingdom.

Done at Brussels, 21.12.2009

For the Commission
Heinz ZOUREK
Director-General